C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Rhea-AI Summary

C4 Therapeutics (Nasdaq: CCCC) has announced that preliminary data from the monotherapy dose escalation portion of their ongoing Phase 1/2 clinical trial of CFT1946 will be presented at the ESMO Congress 2024 in Barcelona, Spain. CFT1946 is a novel BiDAC™ degrader targeting mutant BRAF V600 solid tumors. The presentation, titled 'Preliminary Results from a Phase 1 Study of CFT1946, a Novel BIDAC Degrader in Mutant BRAF V600 Solid Tumors,' will be delivered as a mini oral presentation on September 14, 2024. This presentation marks an important milestone in C4 Therapeutics' development of targeted protein degradation therapies and could provide valuable insights into the potential efficacy of CFT1946 in treating BRAF V600 mutant solid tumors.

Positive

• Preliminary data from Phase 1/2 trial of CFT1946 to be presented at ESMO Congress 2024
• CFT1946 is a novel BiDAC™ degrader targeting mutant BRAF V600 solid tumors
• Presentation selected for mini oral session, indicating potential significance of results

Negative

• None.

WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC™ degrader in mutant BRAF V600 solid tumors, will be presented as a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13 – 17, 2024 in Barcelona, Spain.

Details of the presentation are as follows:

Title: Preliminary Results from a Phase 1 Study of CFT1946, a Novel BIDAC Degrader in Mutant BRAF V600 Solid Tumors
Presentation Date and Time: Saturday, September 14, 2024, 2:45 – 2:50 CEST
Final Publication Number: 612MO
Session Category: Mini oral session
Session Title: Developmental therapeutics
Location: Oviedo Auditorium – Hall 3
Presenter: Maria Vieito, M.D., Msc (Barcelona, Spain, La Coruña)

About C4 Therapeutics

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO^® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

About CFT1946

CFT1946 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against BRAF V600X mutant targets. In preclinical studies, CFT1946 is active in vivo and in vitro in models with BRAF V600E driven disease and in models resistant to BRAF inhibitors. CFT1946 is currently in a Phase 1 dose escalation study in BRAF V600X mutant solid tumors including colorectal cancer, melanoma and non-small cell lung cancer. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT05668585).

Contacts:

Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com

Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com

FAQ

What is the purpose of C4 Therapeutics' (CCCC) Phase 1/2 trial for CFT1946?

The Phase 1/2 trial of CFT1946 aims to evaluate this novel BiDAC™ degrader in patients with mutant BRAF V600 solid tumors. The trial includes a monotherapy dose escalation portion, from which preliminary data will be presented at ESMO Congress 2024.

When and where will C4 Therapeutics (CCCC) present the preliminary results for CFT1946?

C4 Therapeutics will present the preliminary results for CFT1946 at the European Society for Medical Oncology (ESMO) Congress 2024 on September 14, 2024, in Barcelona, Spain. The presentation is scheduled for 2:45 - 2:50 CEST in the Oviedo Auditorium – Hall 3.

What type of cancer is C4 Therapeutics' (CCCC) CFT1946 designed to target?

CFT1946 is designed to target solid tumors with the BRAF V600 mutation. BRAF V600 mutations are commonly found in various types of cancers, including melanoma, colorectal cancer, and thyroid cancer.

What is the significance of C4 Therapeutics' (CCCC) presentation at ESMO Congress 2024?

The presentation at ESMO Congress 2024 is significant as it will provide the first public look at preliminary data from the Phase 1/2 trial of CFT1946. This could offer insights into the potential efficacy and safety of this novel BiDAC™ degrader in treating BRAF V600 mutant solid tumors.